-
公开(公告)号：EP3200770B1
公开(公告)日：2020-09-02
申请号：EP15787314.2
申请日：2015-09-29
-
公开(公告)号：EP3200770A1
公开(公告)日：2017-08-09
申请号：EP15787314.2
申请日：2015-09-29
发明人： DWIVEDI, Anil Kumar , AHMAD, Hafsa , KHANDELWAL, Kiran , SANGWAN, Rajender Singh , SANGWAN, Neelam Singh , GAYEN, Jiaur Rahaman , ., Sarika , BHADUARIA, Smrati , GAUR, Suresh Pratap Singh , BHOSALE, Vivek Vidyadhar , RATH, Srikanta Kumar , SHARMA, Sharad , SHUKLA, Rakesh
摘要： The present invention relates to a formulation useful for delivery of neuro protecting agent. It also demonstrates and discloses a novel delivery system for an extract of a new chemotype of Withania sonmifera (NMITLI118RT+) for neuro- protection against cerebral stroke (signifies concentrated aqueous ethanolic extract of roots of NMITLI-118, a new chemotype of Withania somnifera, a variety of Ashwagandha, which is unique in having high root yield, possessing a uniform crop canopy and uniform composition with respect to its secondary metabolites- withanolides. It is phytochemically characterized by particular abundance of two withanolides i.e. withanone and/or withanolide A, specimens of which are kept in the herbarium of CSIR-CIMAP, Lucknow, India) (Chaurasiya ND, Sangwan RS, Mishra L N, Tuli R, Sangwan N S, Metabolic clustering of a core collection of Indian ginseng Withania somnifera Dunal through DNA, Isoenzyme, polypeptide and withanolide profile diversity-Fitoterapia 2009, 80 (8) 496-505) for neuro- protection against cerebral stroke. Broadly, the invention discloses potent and prudent therapeutic potential of a new formulation using standardized fraction NMITLI118RT+ of a new variety of Withania somnifera (Ashwagandha) for brain function restoration and protection from neurological failures. Particularly the present invention further relates to the process for the preparation of the said formulation containing Standardized NMITLI118RT+ extract, its pharmaceutical compositions, for the management of cerebral stroke. The present invention also 30 relates to a method of treatment of cerebral stroke and comprising of administering the formulation in a predetermined doses and period.
摘要翻译： 本发明涉及用于递送神经保护剂的制剂。 它还展示和公开了用于针对脑中风的神经保护的新型Withania sonmifera（NMITLI118RT +）化学型提取物的新型递送系统（表示NMITLI-118根的浓缩含水乙醇提取物，一种Withania somnifera的新化学型， 各种Ashwagandha，具有独特的高根产量，具有均匀的作物冠层和相对于其次级代谢产物 - 甲酯的均匀组成。其特征在于具有丰富的两种室温毒物，即withanone和/或witooideide A， （Chaurasiya ND，Sangwan RS，Mishra LN，Tuli R，Sangwan NS，通过DNA，同工酶，多肽和蛋白质对印度人参核心藏品Withania somnifera Dunal的代谢聚类） withanolide profile diversity diversity-Fitoterapia 2009,80（8）496-505）用于针对脑中风的神经保护。 概括地说，本发明公开了使用新型睡茄催产素（Ashwagandha）的标准化级分NMITLI118RT +用于脑功能恢复和防止神经失败的新制剂的有效和审慎的治疗潜力。 具体地说，本发明还涉及制备含有标准化NMITLI118RT +提取物的所述制剂的方法，其药物组合物用于控制脑中风。 本发明还涉及一种治疗脑卒中的方法，该方法包括以预定的剂量和时间施用该制剂。
-
搜索结果
2 条记录 (耗时 0.01 秒)
